Patients and Methods: Fifteen patients with recurrent superficial transitional cell bladder carcinoma who experienced prior intravesical therapy failure were studied. Two to 4 weeks after complete ...
Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102 This is an ...
Transitional cell carcinoma (TCC) is the most common form of urinary bladder cancer in dogs, presenting significant challenges in both diagnosis and management. This high‐grade invasive neoplasm ...
Nat Clin Pract Urol. 2007;4(8):432-443. JD Raman is a Chief Resident in Urology and DS Scherr is an Assistant Professor of Urology at the New York Presbyterian Hospital–Weill Cornell Medical Center, ...
A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care. The research, ...
Toward the end of the 19th century, a New York City surgeon named Dr. William Coley purposely injected one of his patients with streptococcal bacteria. Coley wasn’t crazy. He hoped the bacterial ...
When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback